Journals / Journal of Clinical and Analytical Medicine / 2014 / Cilt: 5 - Sayı: 3

Goserelin Tedavisinin Prostatın Transüretral Rezeksiyonu ile İlişkili Kan Kaybı ve Mikrovasküler Dansite Üzerindeki Etkisi

Effects of Goserelin Treatment on Microvessel Density and Blood Loss Associated with Transurethral Resection of the Prostat

Pages
229–233
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: Single dose goserelin treatmentgiven for one month is not effective in reducing blood loss during TURP andhas not suppressive effects on MVD in prostatic tissues.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To determine the effects of one dose goserelin before transurethralresection of the prostate (TUR-P) on blood loss and microvessel density(MVD) of prostatic suburethral tissues in the patients with benign prostatichyperplasia (BPH).
📊
Key Findings & Data:Group-1 consisted of18 patients who were pretreated with 3,6 mgr subcutaneous injection ofgoserelin acetate one month before the operation.
💡
Conclusion & Impact:Discussion: Single dose goserelin treatmentgiven for one month is not effective in reducing blood loss during TURP andhas not suppressive effects on MVD in prostatic tissues.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To determine the effects of one dose goserelin before transurethralresection of the prostate (TUR-P) on blood loss and microvessel density(MVD) of prostatic suburethral tissues in the patients with benign prostatichyperplasia (BPH). Material and Method: The patients who planned to havea TUR-P were randomly divided into two groups. Group-1 consisted of18 patients who were pretreated with 3,6 mgr subcutaneous injection ofgoserelin acetate one month before the operation. Group-2 was constructedfrom 21 patients without goserelin acetate pretreatment. The amount ofintraoperative haemorrhage was calculated. Total blood loss, total bloodloss/duration of surgery and total blood loss/gram of resected tissue werecalculated for each patient. Sections from the prostatic suburethral tissueswere examined for microvessel density. Results: Quantitative decreasesin Hb were greater in group 1 than in group 2, and mean Hb level wasstatistically significantly lower in group 1 than in group 2 at the control justafter the operation (p=0.028). Although all the differences were statisticallyinsignificant, Hb concentration in irrigation fluid and total blood loss duringsurgery were higher in the group 1 than in the group 2, contrarily, blood lossby duration of TURP and blood loss by weight of resected prostate tissuewere less in the group 1 than in the group 2. The MVD was significantly lowerin group 2 than in the group 1. Discussion: Single dose goserelin treatmentgiven for one month is not effective in reducing blood loss during TURP andhas not suppressive effects on MVD in prostatic tissues.

Özet

Amaç: Prostatın transüretral rezeksiyonundan (TUR-P) önce uygulanan tekdoz goserelin in, benign prostat hiperplazisi (BPH) olan hastalarda kan kaybıve prostat subüretral dokunun mikrovasküler dansitesi (MVD) üzerine olan etkilerinin belirlenmesi amaçlandı. Gereç ve Yöntem: TUR-P planlanan hastalariki gruba randomize edilerek ayrıldı. Ameliyattan 1 ay önce 3,6 mg subkütangoserelin asetat uygulanan 18 hasta Grup 1i oluşturdu. Grup 2 ise goserelin verilmeyen 21 hastadan oluşturuldu. İntraoperatif kanama miktarı ölçüldü.Her hasta için toplam kan kaybı, toplam kan kaybı/ ameliyat süresi, toplamkan kaybı/ rezeke edilen doku gramı hesaplandı. Prostat subüretral doku kesitleri mikrovasküler dansitesi açısından incelendi. Bulgular: Ameliyattan hemen sonra yapılan kontrolde; grup 1deki hemoglobin (Hb) düşüşü grup 2yegöre daha fazlaydı ve ortalama Hb seviyesi grup 1de grup 2ye kıyasla istatistiksel olarak anlamlı derecede düşük bulundu (p=0.028). İstatistiksel olarakanlamlı olmamasına rağmen irrigasyon sıvısında Hb konsantrasyonu ve ameliyat süresince kan kaybı grup 1de grup 2ye oranla daha yüksekti, buna karşılık TUR-P süresine göre ve rezeke edilen prostat doku ağırlığına göre kankaybı ise grup 1de grup 2ye gore daha düşüktü. Mikrovasküler dansite grup2de belirgin olarak daha azdı. Tartışma: Bir aylık tek doz goserelin tedavisi,TUR-P boyunca olan kan kaybını azaltmada etkili değildir ve prostat dokusunda mikrovasküler dansitesi üzerinde süpresif etkisi yoktur.

🔖

Cite This Article

KILIC, S., ALTUNOLUK, B., ERGİN, H., KARADAG, N. (2022). Goserelin Tedavisinin Prostatın Transüretral Rezeksiyonu ile İlişkili Kan Kaybı ve Mikrovasküler Dansite Üzerindeki Etkisi. Journal of Clinical and Analytical Medicine, Cilt: 5 - Sayı: 3, 229–233. https://ajindex.com/articles/561180

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluation of 3885 patients. J Urol 1989; 141(2): 243-7
  2. Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168 (5): 2024-6
  3. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finaste- ride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55 (5): 684-9
  4. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58 (6): 972-6
  5. Matzkin H, Chen J, Lewysohn O, Braf Z. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. J Urol 1991; 145 (2): 309-12
  6. Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angio- genesis by androgen deprivation. J Urol 1993; 149 (6): 1553-4
  7. Granados LEA, Chéchile TG, Villavicencio MH. LH-RH agonists as therapeutic alternative in patients with benign prostatic hyperplasia (BPH) and surgical con- traindication. Long term follow up. Arch Esp Urol 1996; 49 (9): 923-7
  8. Fitzpatrick JM, Mebust W. Minimally invasive and endoscopic management of benign prostatic hyperplasia, in: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, Kavoussi LR, Novick AC (Ed): Campbell’s Urology. Philadelphia, PA: Saunders, 2002, vol 2, p. 1379-1416
  9. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int 2000; 85 (1): 70-3
  10. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154 (5): 1779-82
  11. Gormley GJ, Stoner E, Bruskewitz RC, JI Imperato-McGinley, PC Walsh, JD Mc- Connell. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327 (17): 1185-91
  12. Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000; 85 (7): 962-5
  13. Perimenis P, Gyftopoulos K, Markou S, Barbalias G. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology 2002; 5